trending Market Intelligence /marketintelligence/en/news-insights/trending/pwot0hy3kbototehzte3wa2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Spring Bank Pharmaceuticals prices common stock offering

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Spring Bank Pharmaceuticals prices common stock offering

Spring Bank Pharmaceuticals Inc. priced an underwritten public offering of 3 million common shares at $12.50 each.

The Hopkinton, Mass.-based biopharmaceutical company expects to raise gross proceeds of $37.5 million.

Underwriters have a 30-day option to buy up to 450,000 additional common shares at the offering price.

Spring Bank expects the offering, which is subject to customary closing conditions, to close on or about Aug. 13.

Net proceeds will be used on clinical trials, nonclinical studies, research and development as well as general corporate purposes.

Jefferies and Piper Jaffray are acting as joint book-running managers for the offering.